Abstract
Background Opioids can be effective analgesics, but long-term use may be associated with harms. In 2013, the first national, comprehensive, evidence-based pain management guideline was published, from the Scottish Intercollegiate Guideline Network (SIGN 136: Management of Chronic Pain) with key recommendations on analgesic prescribing. This study aimed to examine the potential impact on national opioid prescribing rates in Scotland.
Methods Trends in national and regional community opioid prescribing data for Scotland were analysed from quarter one (Q1) 2005 to Q2 2020. Interrupted time series regression examined the association of SIGN 136 publication with prescribing rates for opioid-containing drugs. Gabapentinoid prescribing was used as an outcome control.
Results After a positive prescribing trend pre-publication, the timing of SIGN 136 publication was associated with a negative change in trend of opioid prescribing rates (−2.82 items per 1,000 population per quarter [PTPPQ]; P<0.01). By Q2 2020, the relative reduction in opioid prescribing rate was -20.67% (95% CI: -23.67, -17.77). This persisted after controlling for gabapentinoid prescribing and was mainly driven by reduction in weak opioids, whereas strong opioid prescribing rates continued to rise. Gabapentinoid prescribing showed a significant rise in level (8.00 items per 1,000 population; P=0.01) and trend (0.27 items PTPPQ; P=0.01) following SIGN 136 publication.
Conclusions Publication of SIGN 136 was associated with a reduction in opioid prescribing rates. This suggests that changes in clinical policy through evidence-based national clinical guidelines may affect community opioid prescribing, though this may be partially replaced by gabapentinoids, and other factors may also contribute.
Competing Interest Statement
L.A.C. chaired the Guideline Development Group for the Scottish Intercollegiate Guideline Network publication, "Management of Chronic Pain" to which this paper refers, proposed an update due to changing evidence, and contributed to the update of the opioids section. She has been Vice Chair of SIGN since October 2020 and was a member of the Scottish Government group that developed the National Prescribing Strategy for Chronic Pain. B.H.S. was a member of the Guideline Development Group for the Scottish Intercollegiate Guideline Network publication, "Management of Chronic Pain" to which this paper refers and contributed to the update of the opioids section. He was the Scottish Government's National Lead Clinician for Chronic Pain (2014 to 2021) and was a member of the Scottish Government group that developed the National Prescribing Strategy for Chronic Pain. D.R.M. is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from the Chief Scientist Office (CSO), Health Data Research UK (HDR-UK) and the National Institute of Health Research (NIHR), outside of the submitted work. H.L.H., and N.T. declare that they have no conflicts of interest.
Funding Statement
No external financial support was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Formal ethical approval was not required as the study used publicly available data which contained no patient or prescriber identifiable information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵3 Joint senior authors
-The title -The study design to include gabapentinoids as a control outcome -The statistical analysis to include opioids stratified by strength, recipients' age and gender.
Data Availability
Summary data used in this study are available from the corresponding author, upon reasonable request. Requests for community prescribing data in Scotland can be made to Public Health Scotland.
